Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing bendamustine alone to bendamustine plus obinutuzumab in rituximab-refractory indolent non-Hodgkin's lymphoma completed with posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Hodgkin's Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2016-11-17